These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 36962838)

  • 1. Safety and immunogenicity of a reduced dose of the BNT162b2 mRNA COVID-19 vaccine (REDU-VAC): A single blind, randomized, non-inferiority trial.
    Pannus P; Depickère S; Kemlin D; Houben S; Neven KY; Heyndrickx L; Michiels J; Willems E; De Craeye S; Francotte A; Chaumont F; Olislagers V; Waegemans A; Verbrugghe M; Schmickler MN; Van Gucht S; Dierick K; Marchant A; Desombere I; Ariën KK; Goossens ME
    PLOS Glob Public Health; 2022; 2(12):e0001308. PubMed ID: 36962838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial.
    Stuart ASV; Shaw RH; Liu X; Greenland M; Aley PK; Andrews NJ; Cameron JC; Charlton S; Clutterbuck EA; Collins AM; Darton T; Dinesh T; Duncan CJA; England A; Faust SN; Ferreira DM; Finn A; Goodman AL; Green CA; Hallis B; Heath PT; Hill H; Horsington BM; Lambe T; Lazarus R; Libri V; Lillie PJ; Mujadidi YF; Payne R; Plested EL; Provstgaard-Morys S; Ramasamy MN; Ramsay M; Read RC; Robinson H; Screaton GR; Singh N; Turner DPJ; Turner PJ; Vichos I; White R; Nguyen-Van-Tam JS; Snape MD;
    Lancet; 2022 Jan; 399(10319):36-49. PubMed ID: 34883053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity, safety, and reactogenicity of a half- versus full-dose BNT162b2 (Pfizer-BioNTech) booster following a two-dose ChAdOx1 nCoV-19, BBIBP-CorV, or Gam-COVID-Vac priming schedule in Mongolia: a randomised, controlled, non-inferiority trial.
    Batmunkh T; Moore KA; Thomson H; Altangerel B; Amraa O; Avaa N; Batbayar L; Batsukh K; Bright K; Burentogtokh T; Ha Do LA; Dorj G; Hart JD; Javkhlantugs K; Jigjidsuren S; Justice F; Li S; Licciardi PV; Mashbaatar K; Mazarakis N; Neal EFG; Nguyen CD; Ochirbat B; Tsolmon B; Tuya A; Surenjav U; von Mollendorf C; Mulholland K
    Lancet Reg Health West Pac; 2024 Jan; 42():100953. PubMed ID: 38357398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.
    Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD;
    Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and safety of simplified vaccination schedules for the CYD-TDV dengue vaccine in healthy individuals aged 9-50 years (CYD65): a randomised, controlled, phase 2, non-inferiority study.
    Coronel-MartÍnez DL; Park J; López-Medina E; Capeding MR; Cadena Bonfanti AA; Montalbán MC; Ramírez I; Gonzales MLA; DiazGranados CA; Zambrano B; Dayan G; Savarino S; Chen Z; Wang H; Sun S; Bonaparte M; Rojas A; Ramírez JC; Verdan MA; Noriega F
    Lancet Infect Dis; 2021 Apr; 21(4):517-528. PubMed ID: 33212067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1-S in adults in the UK (COV-COMPARE): interim analysis of a randomised, controlled, phase 3, immunobridging trial.
    Lazarus R; Querton B; Corbic Ramljak I; Dewasthaly S; Jaramillo JC; Dubischar K; Krammer M; Weisova P; Hochreiter R; Eder-Lingelbach S; Taucher C; Finn A;
    Lancet Infect Dis; 2022 Dec; 22(12):1716-1727. PubMed ID: 36075233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of the Vi-DT typhoid conjugate vaccine in healthy volunteers in Nepal: an observer-blind, active-controlled, randomised, non-inferiority, phase 3 trial.
    Kumar Rai G; Saluja T; Chaudhary S; Tamrakar D; Kanodia P; Giri BR; Shrestha R; Uranw S; Kim DR; Yang JS; Park IY; Kyung SE; Vemula S; Reddy E J; Kim B; Gupta BP; Jo SK; Ryu JH; Park HK; Shin JH; Lee Y; Kim H; Kim JH; Mojares ZR; Wartel TA; Sahastrabuddhe S
    Lancet Infect Dis; 2022 Apr; 22(4):529-540. PubMed ID: 34942090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and reactogenicity of heterologous and homologous mRNA-1273 and BNT162b2 vaccination: A multicenter non-inferiority randomized trial.
    Janssen C; Cachanado M; Ninove L; Lachatre M; Michon J; Epaulard O; Maakaroun-Vermesse Z; Chidiac C; Laviolle B; Aumaitre H; Assaf A; Lacombe K; Schmidt-Mutter C; Botelho-Nevers E; Briere M; Boisson T; Loubet P; Bienvenu B; Bouchaud O; Touati A; Pereira C; Rousseau A; Berard L; Montil M; de Lamballerie X; Simon T; Launay O;
    EClinicalMedicine; 2022 Jun; 48():101444. PubMed ID: 35582124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and safety of a novel ten-valent pneumococcal conjugate vaccine in healthy infants in The Gambia: a phase 3, randomised, double-blind, non-inferiority trial.
    Clarke E; Bashorun A; Adigweme I; Badjie Hydara M; Umesi A; Futa A; Ochoge M; Obayemi D; Edem B; Saidy-Jah E; Onwuchekwa C; Dhere R; Sethna V; Kampmann B; Goldblatt D; Taylor D; Andi-Lolo I; Hosken N; Antony K; Innis BL; Alderson MR; Lamola S
    Lancet Infect Dis; 2021 Jun; 21(6):834-846. PubMed ID: 33516293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials.
    Yang S; Li Y; Dai L; Wang J; He P; Li C; Fang X; Wang C; Zhao X; Huang E; Wu C; Zhong Z; Wang F; Duan X; Tian S; Wu L; Liu Y; Luo Y; Chen Z; Li F; Li J; Yu X; Ren H; Liu L; Meng S; Yan J; Hu Z; Gao L; Gao GF
    Lancet Infect Dis; 2021 Aug; 21(8):1107-1119. PubMed ID: 33773111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials.
    Zhu F; Zhuang C; Chu K; Zhang L; Zhao H; Huang S; Su Y; Lin H; Yang C; Jiang H; Zang X; Liu D; Pan H; Hu Y; Liu X; Chen Q; Song Q; Quan J; Huang Z; Zhong G; Chen J; Han J; Sun H; Cui L; Li J; Chen Y; Zhang T; Ye X; Li C; Wu T; Zhang J; Xia NS
    Lancet Respir Med; 2022 Aug; 10(8):749-760. PubMed ID: 35644168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
    Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
    Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and safety of booster CYD-TDV dengue vaccine after alternative primary vaccination schedules in healthy individuals aged 9-50 years: a randomised, controlled, phase 2, non-inferiority study.
    Coronel-Martinez DL; Park J; López-Medina E; Capeding MR; Bonfanti AAC; Montalbán MC; Ramírez I; Gonzales MLA; Zambrano B; Dayan G; Chen Z; Wang H; Bonaparte M; Rojas A; Ramírez JC; Verdan MA; Noriega F
    Lancet Infect Dis; 2022 Jun; 22(6):901-911. PubMed ID: 35364022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial.
    Borobia AM; Carcas AJ; Pérez-Olmeda M; Castaño L; Bertran MJ; García-Pérez J; Campins M; Portolés A; González-Pérez M; García Morales MT; Arana-Arri E; Aldea M; Díez-Fuertes F; Fuentes I; Ascaso A; Lora D; Imaz-Ayo N; Barón-Mira LE; Agustí A; Pérez-Ingidua C; Gómez de la Cámara A; Arribas JR; Ochando J; Alcamí J; Belda-Iniesta C; Frías J;
    Lancet; 2021 Jul; 398(10295):121-130. PubMed ID: 34181880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity of a Fractional Dose of mRNA BNT162b2 COVID-19 Vaccine for Primary Series and Booster Vaccination among Healthy Adolescents.
    Puthanakit T; Chantasrisawad N; Yoohat K; Nantanee R; Sophonphan J; Meepuksom T; Sodsai P; Phanthanawiboon S; Jantarabenjakul W; Hirankarn N; Kosalaraksa P
    Vaccines (Basel); 2022 Sep; 10(10):. PubMed ID: 36298510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: A randomised, placebo-controlled, observer-blinded phase 1/2 trial.
    Song JY; Choi WS; Heo JY; Lee JS; Jung DS; Kim SW; Park KH; Eom JS; Jeong SJ; Lee J; Kwon KT; Choi HJ; Sohn JW; Kim YK; Noh JY; Kim WJ; Roman F; Ceregido MA; Solmi F; Philippot A; Walls AC; Carter L; Veesler D; King NP; Kim H; Ryu JH; Lee SJ; Park YW; Park HK; Cheong HJ
    EClinicalMedicine; 2022 Sep; 51():101569. PubMed ID: 35879941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and safety of BNT162b2 mRNA vaccine in Chinese adults: A phase 2 randomised clinical trial.
    Hui AM; Li J; Zhu L; Tang R; Ye H; Lin M; Ge L; Wang X; Peng F; Wu Z; Guo X; Shi Y; Pan H; Zhu J; Song Z; Qiu J; Wang W; Zheng J; Ozhelvaci O; Shpyro S; Bushway M; Derhovanessian E; Kühnle MC; Luxemburger U; Muik A; Shishkova Y; Khondker Z; Hu S; Lagkadinou E; Şahin U; Türeci Ö; Zhu F
    Lancet Reg Health West Pac; 2022 Dec; 29():100586. PubMed ID: 36120090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial.
    Shaw RH; Liu X; Stuart ASV; Greenland M; Aley PK; Andrews NJ; Cameron JC; Charlton S; Clutterbuck EA; Collins AM; Dejnirattisai W; Dinesh T; Faust SN; Ferreira DM; Finn A; Green CA; Hallis B; Heath PT; Hill H; Lambe T; Lazarus R; Libri V; Long F; Mujadidi YF; Plested EL; Morey ER; Provstgaard-Morys S; Ramasamy MN; Ramsay M; Read RC; Robinson H; Screaton GR; Singh N; Turner DPJ; Turner PJ; Vichos I; Walker LL; White R; Nguyen-Van-Tam JS; Snape MD;
    Lancet Respir Med; 2022 Nov; 10(11):1049-1060. PubMed ID: 35690076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in healthy adults: phase 1/2, randomised, double-blind, active comparator-controlled, multicentre, US-based trial.
    Platt H; Omole T; Cardona J; Fraser NJ; Mularski RA; Andrews C; Daboul N; Gallagher N; Sapre A; Li J; Polis A; Fernsler D; Tamms G; Xu W; Murphy R; Skinner J; Joyce J; Musey L
    Lancet Infect Dis; 2023 Feb; 23(2):233-246. PubMed ID: 36116461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.